{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:56:36Z","timestamp":1791140196383,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.imlet.2013.09.015","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T18:02:23Z","timestamp":1380650543000},"page":"36-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Reprogramming cell death: BCL2 family inhibition in hematological malignancies"],"prefix":"10.1016","volume":"155","author":[{"given":"Lydia","family":"Scarf\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2013.09.015_bib0005","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/cdd.2011.17","article-title":"The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy","volume":"18","author":"Kelly","year":"2011","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.imlet.2013.09.015_bib0010","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.imlet.2013.09.015_bib0015","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2007-09-078162","article-title":"Bcl-2-family proteins and hematologic malignancies: history and future prospects","volume":"111","author":"Reed","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.V91.1.244","article-title":"Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival","volume":"91","author":"Ghia","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0025","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1182\/blood.V90.3.1168","article-title":"BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma","volume":"90","author":"Monni","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0030","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"BCL-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0035","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imlet.2013.09.015_bib0040","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","article-title":"Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers","volume":"112","author":"Pepper","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.imlet.2013.09.015_bib0050","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2013.09.015_bib0055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/cdd.2008.137","article-title":"Bcl-2 inhibitors: small molecules with a big impact on cancer therapy","volume":"16","author":"Vogler","year":"2009","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.imlet.2013.09.015_bib0060","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.imlet.2013.09.015_bib0065","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10428199309086993","article-title":"The role of Bcl-2 in the pathogenesis of B chronic lymphocytic leukemia","volume":"11","author":"Schena","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.imlet.2013.09.015_bib0070","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O\u2019Brien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2013.09.015_bib0075","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2006.07.1191","article-title":"Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"25","author":"O\u2019Brien","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2013.09.015_bib0080","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1200\/JCO.2009.22.5748","article-title":"5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen","volume":"27","author":"O\u2019Brien","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.imlet.2013.09.015_bib0085","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1038\/onc.2009.52","article-title":"Mimicking the BH3 domain to kill cancer cells","volume":"27","author":"Ni Chonghaile","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.imlet.2013.09.015_bib0090","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.imlet.2013.09.015_bib0095","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.09.015_bib0100","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V118.21.2865.2865","article-title":"Obatoclax in combination with fludarabine and rituximab (FR) is well-tolerated and shows promising clinical activity in relapsed CLL\/SLL","volume":"118","author":"Brown","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0105","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood.V108.11.2838.2838","article-title":"A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"108","author":"Castro","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0110","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2013.09.015_bib0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2013.09.015_bib0120","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1182\/blood.V118.21.3904.3904","article-title":"Navitoclax (ABT-263) plus fludarabine\/cyclophosphamide\/rituximab (FCR) or bendamustine\/rituximab (BR): a phase 1 study in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL)","volume":"118","author":"Kipps","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0125","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","article-title":"ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia","volume":"121","author":"Vandenberg","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2013.09.015_bib0130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"suppl","key":"10.1016\/j.imlet.2013.09.015_bib0135","article-title":"Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory non-Hodgkin lymphoma (NHL)","volume":"31","author":"Davids","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.imlet.2013.09.015_bib0140","article-title":"Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL)","volume":"31","author":"Seymour","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.imlet.2013.09.015_bib0145","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247813001387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247813001387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T04:16:32Z","timestamp":1596600992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247813001387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0165247813001387"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2013.09.015","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reprogramming cell death: BCL2 family inhibition in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2013.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}